Studies of interferences of apomorphine and its metabolites or decomposition products with immunochemical screening tests for legal and illicit drugs after therapeutic doses of apomorphine.
This study deals with the question of whether apomorphine (CAS 314-19-2; e.g. in Ixense) and its metabolites or decomposition products interfere with the specificity of immunochemical screening tests (immunoassays) for legal and illicit drugs. It was the result of the investigations that after the therapeutic use of apomorphine no relevant false-positive screening findings were observed with the CEDIA (cloned enzyme donor immuno assay) and FPIA (fluorescence polarisation immuno assay) tests, which are commonly encountered in drug-screening programs, when using recommended cut-off values for urine.
Schütz
Harald
H
Institut für Rechtsmedizin, Universität Giessen, Giessen, Germany. harald.f.schuetz@forens.med.uni-giessen.de
Erdmann
Freidoon
F
Risse
Manfred
M
Weiler
Günter
G
D001058:Apomorphine / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000652:urine*; D015415:Biomarkers / Q000032:analysis; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D005189:False Positive Reactions; D016231:Fluorescence Polarization Immunoassay; D006801:Humans; D007120:Immunochemistry; D015813:Substance Abuse Detection / Q000379:methods*
D015415:Biomarkers; D001058:Apomorphine